Private equity group Carlyle has been outbid in its attempt to take control of the UK’s Vectura group, after tobacco industry giant Philip Morris International submitted a superior offer of £1.50 ($2.06) per share. The offer represents a 10% increase over Carlyle’s offer of £1.36 per share.
Philip Morris Bid For Vectura Trumps Carlyle Takeover
UK-Based Respiratory Specialist Recommends Shareholders Back 10% Higher Offer
Tobacco giant Philip Morris International has swept in with a superior offer for the UK’s Vectura group, outbidding Carlyle after its takeover attempt was announced in May. Vectura is recommending that its shareholders back the improved offer.
More from Deals
More from Business
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.